Abstract
The aim of this study was to establish the efficacy and safety of rituximab in refractory nephrotic syndrome (NS). Members of the International Paediatric Nephrology Association were asked to retrospectively fill in a questionnaire with details on the use of rituximab in their centres. We divided the data into three groups: group 1, patients with steroid-dependent and frequently relapsing NS; group 2, with steroid-resistant NS; group 3, with post-transplant recurrence of NS. Seventy questionnaires from 25 centres described the outcome of 28, 27 and 15 patients in groups 1, 2 and 3, respectively. Of these, 82% of patients in group 1, 44% of patients in group 2 and 60% of patients in group 3 had a good initial response. Side effects were observed in 27% of the patients, and these were mostly acute reactions. We present a large multicentre series of children with refractory NS. Children in group 1 showed the best response. The good initial response in group 3 can be biased by the accompanying treatments that were administered at the same time as rituximab. Controlled prospective trials are required to establish the value of rituximab in idiopathic NS.
Similar content being viewed by others
Abbreviations
- ACE-I:
-
angiotensin converting enzyme inhibitors
- CI:
-
calcineurin inhibitors
- FRNS:
-
frequently relapsing nephrotic syndrome
- FSGS:
-
focal and segmental glomerulosclerosis
- MCNS:
-
minimal change nephrotic syndrome
- MMF:
-
mycophenolate mofetil
- NS:
-
nephrotic syndrome
- PML:
-
progressive multifocal leukoencephalopathy
- PTLD:
-
post-transplant lymphoproliferative disorders
- SDNS:
-
steroid-dependent nephrotic syndrome
- SLE:
-
systemic lupus erythematosus
- SRNS:
-
steroid-resistant nephrotic syndrome
References
Barratt M, Clark G (1994) Minimal change nephrotic syndrome and focal segmental glomerulosclerosis. In: Holliday M, Barratt M, Avner E (eds) Pediatric Nephrology, 3rd edn. Lippincott Williams & Wilkins, Philadelphia, pp 767–787
Ehrich JH, Geerlings C, Zivicnjak M, Franke D, Geerlings H, Gellermann J (2007) Steroid-resistant idiopathic childhood nephrosis: overdiagnosed and undertreated. Nephrol Dial Transplant 22:2183–2193
Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC (2005) Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol 16:1061–1068
Colquitt J, Kirby J, Green C, Cooper K, Trompeter R (2007) The clinical effectiveness and cost-effectiveness of treatments for children with idiopathic steroid-resistant nephrotic syndrome: a systematic review. Health Technol Assess 11:5–7
Smith GC (2007) Is there a role for rituximab in the treatment of idiopathic childhood nephrotic syndrome? Pediatr Nephrol 22:893–898
Benz K, Dötsch J, Rascher W, Stachel D (2004) Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol 19:794–797
Gilbert RD, Hulse E, Rigden S (2006) Rituximab therapy for steroid-dependent minimal change nephrotic syndrome. Pediatr Nephrol 21:1698–1700
Nakayama M, Kamei K, Nozu K, Matsuoka K, Nakagawa A, Sako M, Iijima K (2008) Rituximab for refractory focal segmental glomerulosclerosis. Pediatr Nephrol 23:481–485
Suri M, Tran K, Sharma AP, Filler G, Grimmer J (2008) Remission of steroid-resistant nephrotic syndrome due to focal and segmental glomerulosclerosis using rituximab. Int Urol Nephrol 40:807–810
Hristea D, Hadaya K, Marangon N, Buhler L, Villard J, Morel P, Martin PY (2007) Successful treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation by plasmapheresis and rituximab. Transpl Int 20:102–105
Cochat P, Kassir A, Colon S, Glastre C, Tourniaire B, Parchoux B, Martin X, David L (1993) Recurrent nephrotic syndrome after transplantation: early treatment with plasmaphaeresis and cyclophosphamide. Pediatr Nephrol 7:50–54
Guigonis V, Dallocchio A, Baudouin V, Dehennault M, Hachon-Le Camus C, Afanetti M, Groothoff J, Llanas B, Niaudet P, Nivet H, Raynaud N, Taque S, Ronco P, Bouissou F (2008) Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol 23:1269–1279
Bagga A, Sinha A, Moudgil A (2007) Rituximab in patients with the steroid-resistant nephrotic syndrome. N Engl J Med 356:2751–2752
Nozu K, Iijima K, Fujisawa M, Nakagawa A, Yoshikawa N, Matsuo M (2005) Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome. Pediatr Nephrol 20:1660–1663
Pescovitz MD, Book BK, Sidner RA (2006) Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment. N Engl J Med 354:1961–1963
Marks SD, McGraw M (2007) Does rituximab treat recurrent focal segmental glomerulosclerosis post-renal transplantation? Pediatr Nephrol 22:158–160
Yabu JM, Ho B, Scandling JD, Vincenti F (2008) Rituximab failed to improve nephrotic syndrome in renal transplant patients with recurrent focal segmental glomerulosclerosis. Am J Transplant 8:222–227
Parodi E, Nobili B, Perrotta S, Rosaria Matarese SM, Russo G, Licciardello M, Zecca M, Locatelli F, Cesaro S, Bisogno G, Giordano P, De Mattia D, Ramenghia U (2006) Rituximab (anti-CD20 monoclonal antibody) in children with chronic refractory symptomatic immune thrombocytopenic purpura: efficacy and safety of treatment. Int J Hematol 84:48–53
Sharma AP, Filler G (2009) Role of mycophenolate mofetil in remission maintenance after a successful response to rituximab. Pediatr Nephrol 24:423–424
Kamei K, Ito S, Nozu K, Fujinaga S, Nakayama M, Sako M, Saito M, Yoneko M, Iijima K (2009) Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol 24:1321–1328
Podolskaya A, Stadermann M, Pilkington C, Marks SD, Tullus K (2008) B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus. Arch Dis Child 93:401–406
Calabrese LH, Molloy ES (2008) Progressive multifocal leukoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies. Ann Rheum Dis 67[Suppl 3]:64–65
Molloy ES, Calabrese LH (2008) Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk? Autoimmun Rev 8:144–146
Acknowledgments
We thank the International Pediatric Nephrology Association for help in the distribution of questionnaires. We are very grateful to all paediatric nephrologists who contributed to this study by submitting data on their patients: B. Ahmed (Dubai, UAE), L. Al-Khalidi, (Dubai, UAE), A. Amore (Torino, Italy), I. Al Attrach (Abu Dhabi, UAE), J. Baluarte (Philadelphia, USA), D. Ben-Ezer (Orange CA, USA), V. de Barros Bittencourt (Porto Alegre, Brazil), J. Booth (Newcastle upon Tyne, UK), J. Chen (Toronto, Canada), R. Coppo (Torino, Italy), C. Crompton (Perth, Australia), K. Fidan (Ankara, Turkey), A. Gür Güven (Antalya, Turkey), R. Hani Hadidi (Amman, Jordan), E. Harvey (Toronto, Canada), D. Hebert (Toronto, Canada), J. Huang (Beijing, China), S. Hulton (Birmingham, UK), F. Hussain (Nottingham, UK), L. Hyla-Klekot (Chorzow, Poland), B. Kaplan (Philadelphia, USA), L. Peruzzi (Torino, Italy), V. Pinto (Santiago, Chile), G. Porcellini (Torino, Italy), I. Roberti (New York, USA), E. Simon (Albany, USA), O. Söylemezoğlu (Ankara, Turkey), K. Van Hoeck (Antwerp, Belgium).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Prytuła, A., Iijima, K., Kamei, K. et al. Rituximab in refractory nephrotic syndrome. Pediatr Nephrol 25, 461–468 (2010). https://doi.org/10.1007/s00467-009-1376-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-009-1376-6